Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

FibroBiologics, Inc. - Common Stock (NQ:FBLG)

0.2628 +0.0128 (+5.12%)
Streaming Delayed Price Updated: 1:15 PM EST, Feb 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 117,396
Open 0.2500
Bid (Size) 0.2603 (100)
Ask (Size) 0.2682 (500)
Prev. Close 0.2500
Today's Range 0.2500 - 0.2666
52wk Range 0.2201 - 1.530
Shares Outstanding 38,262,586
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Get insights into the top gainers and losers of Wednesday's after-hours session. ↗
Via Chartmill
News headline image
FibroBiologics’ Chairman & CEO Pete O’Heeron Selected to Present at A4LI’s H-SPAN Summit at Georgetown University
From FibroBiologics, Inc.
Via GlobeNewswire

Performance

YTD
+9.5%
+9.5%
1 Month
-18.5%
-18.5%
3 Month
-19.0%
-19.0%
6 Month
-55.4%
-55.4%
1 Year
-77.1%
-77.1%

More News

Read More
News headline image
FibroBiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for Cachexia
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics to Present at the DealFlow Discovery Conference
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics CEO Issues Letter to Shareholders
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte (FSdC) Spheroid Therapy for Degenerative Disc Disease
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Files IND Application with the U.S. FDA to Advance Clinical Development of CYPS317 in Patients with Psoriasis
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Announces Closing of $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
Monday's session: top gainers and losers ↗
Via Chartmill
News headline image
Which stocks are gapping on Monday? ↗
Via Chartmill
News headline image
Monday's pre-market session: top gainers and losers ↗
Via Chartmill
News headline image
FibroBiologics Announces $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Files Patent Application Covering Novel Fibroblast-Based Chondrocyte Spheroid Platform for Orthopedic and Musculoskeletal Conditions
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Announces Payoff of Outstanding Debt
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Announces Closing of $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
Which stocks are experiencing notable movement on Monday? ↗
Via Chartmill
News headline image
Top movers in Monday's session ↗
Via Chartmill
News headline image
The market is filled with gapping stocks in Monday's session. ↗
Via Chartmill
News headline image
FibroBiologics Announces $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Receives HREC Approval for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Via Benzinga
News headline image
FibroBiologics Announces Pricing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Via Benzinga

Frequently Asked Questions

Is FibroBiologics, Inc. - Common Stock publicly traded?
Yes, FibroBiologics, Inc. - Common Stock is publicly traded.
What exchange does FibroBiologics, Inc. - Common Stock trade on?
FibroBiologics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for FibroBiologics, Inc. - Common Stock?
The ticker symbol for FibroBiologics, Inc. - Common Stock is FBLG on the Nasdaq Stock Market
What is the current price of FibroBiologics, Inc. - Common Stock?
The current price of FibroBiologics, Inc. - Common Stock is 0.2628
When was FibroBiologics, Inc. - Common Stock last traded?
The last trade of FibroBiologics, Inc. - Common Stock was at 02/20/26 01:15 PM ET
What is the market capitalization of FibroBiologics, Inc. - Common Stock?
The market capitalization of FibroBiologics, Inc. - Common Stock is 10.06M
How many shares of FibroBiologics, Inc. - Common Stock are outstanding?
FibroBiologics, Inc. - Common Stock has 10M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.